About Can-Fite BioPharma
Can-Fite BioPharma Ltd is an SEC registrant, classified under SIC 2834 (Pharmaceutical Preparations). It files with the SEC under Central Index Key 0001536196, and its shares are listed as CANF on NYSE American. Its most recent filing on EDGAR is a 6-K, filed November 18, 2026. 12 institutional investment managers reported holding its shares on Form 13F for Q3 2026, against 9 in Q2 2026. Its officers, directors and 10% owners have filed 2 Form 4 reports since 2026. 1 registered fund reports holding its shares on Form N-PORT.
Across SEC filings
Institutional holders · 13F
Q3 2026| Largest holders | Reported value |
|---|---|
| SABBY MANAGEMENT LLC | $187.5K |
| CITADEL ADVISORS LLC | $59.2K |
| RHUMBLINE ADVISERS | $42.8K |
| JANE STREET GROUP LLC | $29.3K |
| GAMMA Investing LLC | $14.8K |
Securities
| CUSIP | Security | Type |
|---|---|---|
| 13471N409 | CANF CAN FITE BIOPHARMA LTD-ADR | Adr |
Insider trades · Form 4
No open-market purchases or sales by Can-Fite BioPharma insiders in the last 12 months.
Latest filings
- Motti Farbstein 2026-06-08 Award
- Pnina Fishman 2026-06-08 Award
Funds & ETFs · N-PORT
1 fund| Fund | Value | % of fund |
|---|---|---|
| Blackstone Alternative Multi-Strategy Fund | $149 | < 0.01% |
1 fund reported holding $149 in total on their latest public Form N-PORT reports, the most recent dated June 2026. Security record